NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 15 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Fermenta Biotech Q2 Revenue at ₹135.8 Cr, PAT Falls 48% YoY to ₹9.4 Cr Amid Animal Nutrition Reset
Fermenta Biotech reported flat Q2FY27 consolidated revenue of ₹135.8 crore (up 0.1% YoY, up 8% QoQ), while PAT declined 48% YoY to ₹9.4 crore. For H1FY27, revenue fell 7% YoY to ₹261.9 crore and PAT dropped 52% YoY to ₹18.9 crore, impacted by a sharp price and volume reset in animal nutrition where revenue dropped from ₹46 crore to ₹22 crore. Despite profitability headwinds, H1 operating cash flow rose 44% to ₹54.8 crore on working capital release, bringing net debt down below ₹3 crore. Strategic growth drivers include ₹60 crore Dahej capex for VITADEE Green® with commercial capacity expected from Q2FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுFermenta Biotech shared its Q2/H1FY27 investor presentation highlighting performance metrics, product segment breakdowns, and project timelines.
ஏன் இது முக்கியம்The earnings underscore a cyclical downturn in the animal nutrition Vitamin D3 segment, partially offset by resilient human nutrition sales and stronger operating cash flows.
📅 குறுகிய காலம்Margin pressures from price resets in animal nutrition and lower YoY profitability may keep short-term sentiment cautious.
📈 நீண்ட காலம்A near-zero net debt balance sheet and diversification into high-value products like plant-based VITADEE Green® and Calcifediol offer structural upside if execution stays on track.
⚠ அபாய எச்சரிக்கைகள்
Prolonged price and volume depression in the animal nutrition business
Customer or geographic concentration shifts as India contribution rose to 51%
👀 கவனிக்க வேண்டியவை
Track the stabilization of animal nutrition prices and regulatory approvals for Calcifediol expected by end-FY27. Monitor progress on the Dahej expansion planned for Q2FY28.
Fermenta Biotech H1FY27 Revenue Down 7% YoY to ₹261.9 Cr; PAT Drops 52% to ₹18.9 Cr
Fermenta Biotech reported H1FY27 consolidated revenue of ₹261.9 crore, down 7% YoY, primarily dragged down by its Animal Nutrition Vitamin D3 segment which plunged 52% YoY to ₹22.1 crore due to lower volumes and prices. Consolidated EBITDA dropped 34% YoY to ₹45.6 crore, while PAT declined 52% YoY to ₹18.9 crore, also impacted by non-repeat of high base other income. For Q2FY27, revenue stood flat YoY at ₹135.8 crore (+8% QoQ) with PAT at ₹9.4 crore (-48% YoY). Meanwhile, Human Nutrition Vitamin D3 held steady, growing 2% YoY to ₹162.5 crore and accounting for almost two-thirds of revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுFermenta Biotech released its H1FY27 and Q2FY27 financial press release, disclosing a sharp drop in animal nutrition earnings alongside subsidiary EBITDA losses.
ஏன் இது முக்கியம்Animal nutrition price erosions and high-base one-offs heavily compressed operating margins (EBITDA down 34%), forcing the business to rely more heavily on Human Nutrition and domestic sales (now 51% of revenue).
📅 குறுகிய காலம்Weak earnings performance and subsidiary-level EBITDA losses are likely to weigh on sentiment, despite flat Q2 revenue and sequential volume uptick in Human Nutrition.
📈 நீண்ட காலம்Structural recovery hinges on animal nutrition price recovery, regulatory approvals for Calcifediol (targeted by end-FY27), and commercial scale-up of VITADEE Green® capacities from Q2FY28.
⚠ அபாய எச்சரிக்கைகள்
Pricing vulnerability in Animal Nutrition Vitamin D3 segment (realisations down 35% YoY)
Operating losses across German, US, and Environmental subsidiaries in H1FY27
👀 கவனிக்க வேண்டியவை
Track the stabilization of Vitamin D3 animal nutrition pricing cycles and monitor progress toward commercial capacity readiness of plant-sourced VITADEE Green® targeted for Q2FY28.
Fermenta Biotech Q2 FY27 Standalone PAT at ₹13.95 Cr, Revenue up 9.2% YoY to ₹116.94 Cr
Fermenta Biotech reported standalone revenue from operations of ₹116.94 Cr for Q2 FY27, up 9.2% YoY from ₹107.12 Cr in Q2 FY26. Standalone net profit stood at ₹13.95 Cr, declining 5.2% YoY compared to ₹14.72 Cr in the prior-year period. Profit before tax fell 9.7% YoY to ₹18.77 Cr due to higher finance costs and operational expenses. Separately, the company identified its 'Environment' business as an independent reportable segment under Ind AS 108.
உச்சம் நம்பிக்கை
என்ன மாறியதுFermenta Biotech declared Q2 FY27 results showing modest revenue expansion but slightly depressed standalone profit, while carving out Environment business as a reportable segment.
ஏன் இது முக்கியம்Operating profitability saw pressure from higher finance costs despite top-line growth, signaling margin compression relative to FY26 run-rates.
Standalone Revenue Q2 FY27: ₹11,693.63 லட்சம்Standalone PAT Q2 FY27: ₹1,395.36 லட்சம்Basic EPS (Q2 FY27): ₹4.86Finance Costs (Q2 FY27): ₹373.30 லட்சம்
📅 குறுகிய காலம்The market is likely to react neutrally to mildly soft given modest single-digit top-line growth offset by a contraction in net profit.
📈 நீண்ட காலம்Performance will hinge on the core pharma business maintaining margin stability and the emerging Environment segment generating scalable returns.
⚠ அபாய எச்சரிக்கைகள்
Rising finance costs (up 44% YoY to ₹3.73 Cr)
Moderation in net profit margin YoY
👀 கவனிக்க வேண்டியவை
Track the growth and margin performance of the newly separated Environment segment, alongside operating margin trajectory against the TTM average of 17.6%.
Promoter Preeti Thakkar has sold 11,65,938 equity shares, representing 3.96% of the share capital of Fermenta Biotech Limited, via an open market transaction on September 28, 2026. Following the sale, her individual holding has decreased from 7.61% (22,40,376 shares) to 3.65% (10,74,438 shares). At current market prices, the sold stake represents approximately Rs 54.7 crore in value against the company's total market cap of Rs 1,351 crore. Total promoter group holding stood at 64.08% prior to this transaction.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoter Preeti Thakkar reduced her personal stake by more than half, offloading a 3.96% stake via an open-market sale.
ஏன் இது முக்கியம்Open-market promoter selling of ~4% equity can create short-term supply pressure, though the promoter group retains majority control overall.
📅 குறுகிய காலம்May cause short-term price overhang due to secondary market supply absorption following the open-market sale.
📈 நீண்ட காலம்Limited operational impact, though sustained selling by promoter entities would be a monitorable factor.
⚠ அபாய எச்சரிக்கைகள்
Open-market promoter stake reduction
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly shareholding pattern to see the overall change in aggregate promoter group holding and whether institutional buyers absorbed the block.
CARE Upgrades Fermenta Biotech's Long-Term Rating to 'BBB+' on Rs 172.98 Cr Bank Facilities
CARE Ratings Limited has upgraded Fermenta Biotech's credit ratings across its bank facilities totalling Rs 172.98 crore. The rating for long-term bank facilities was upgraded to 'CARE BBB+; Stable' from 'CARE BBB; Stable', with the rated limit enhanced to Rs 166.73 crore from Rs 118.94 crore. Short-term bank facilities of Rs 6.25 crore were upgraded to 'CARE A2' from 'CARE A3+'. The upgrade reflects an improved credit risk profile relative to the company's existing debt of Rs 113 crore and net worth of Rs 406 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings upgraded Fermenta Biotech's long-term rating from BBB to BBB+ (Stable) and short-term rating from A3+ to A2 on total bank facilities of Rs 172.98 crore.
ஏன் இது முக்கியம்The upgrade signals improved creditworthiness, potentially lowering borrowing costs and expanding financial flexibility for operational and capital requirements.
Total rated bank facilities: Rs 172.98 croreLong-term bank facilities: Rs 166.73 crore (enhanced from Rs 118.94 crore)Short-term bank facilities: Rs 6.25 croreTotal rated facilities vs TTM revenue: ~34.5%
📅 குறுகிய காலம்Positive for market sentiment, though direct immediate P&L impact will depend on loan renegotiations with lenders.
📈 நீண்ட காலம்Enhances the company's funding access and cost efficiency as it scales operations on a low debt-to-equity base (0.28x).
⚠ அபாய எச்சரிக்கைகள்
Potential increase in interest burden if enhanced limits of Rs 166.73 crore are heavily drawn
👀 கவனிக்க வேண்டியவை
Track whether the credit rating upgrade leads to lower borrowing costs in upcoming quarterly finance costs, and monitor debt utilization from the enhanced facilities.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Fermenta Biotech Approves ₹3.75 Dividend and ₹100 Cr Related Party Transaction at 74th AGM
Fermenta Biotech concluded its 74th Annual General Meeting, where shareholders approved a final dividend of ₹3.75 per share (75% of face value) for FY26. A key resolution passed was the approval for material related party transactions with its subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crore. This transaction limit is significant, representing approximately 19% of the company's TTM revenue of ₹525 crore. Additionally, the company authorized a commission of up to 1% of net profits for non-executive directors.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have formally ratified the FY26 financial statements, the dividend payout, and established a ₹100 crore ceiling for transactions with the US subsidiary.
ஏன் இது முக்கியம்The approval of a ₹100 crore transaction limit with the US subsidiary indicates the company's expectation of significant business volume in the North American market, which is critical for its pharmaceutical exports.
Dividend per share: ₹3.75RPT Limit (Fermenta USA): ₹100 கோடிRPT vs TTM Revenue: ~19%Director Commission Limit: 1% of net profitsDividend Payment Deadline: ஆகஸ்ட் 21, 2026
📅 குறுகிய காலம்The stock may see minor activity around the dividend payment date of August 21, but the announcement is largely procedural and expected.
📈 நீண்ட காலம்The structural focus remains on the company's ability to maintain its 19% OPM while scaling international operations through its US subsidiary.
⚠ அபாய எச்சரிக்கைகள்
Related party transactions with subsidiary (₹100 crore limit)
👀 கவனிக்க வேண்டியவை
Investors should monitor the quarterly revenue contribution from the US subsidiary to see if the ₹100 crore transaction limit translates into actual sales growth.
₹110 Cr Capex Approved for Vitamin D3 Expansion; FY26 Revenue Hits Record ₹548 Cr
Fermenta Biotech reported a record FY26 revenue of ₹548 Cr, up 14% YoY, with core EBITDA (excluding real estate) rising 44% to ₹120 Cr. The Board has approved a significant ₹110 Cr capex for expanding plant-source Vitamin D3 and biocatalysis enzymes at the Dahej facility, representing ~21% of TTM revenue. While PAT fell to ₹70 Cr from ₹76 Cr, the prior year was inflated by a ₹45 Cr one-off real estate gain, indicating improved core profitability. Free cash flow tripled to ₹62 Cr, providing a strong cushion for the planned expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a recovery phase to a growth phase, backed by a major capex approval and a strategic shift toward high-value, patent-protected plant-source vitamins.
ஏன் இது முக்கியம்The ₹110 Cr investment is a significant capacity expansion (21% of revenue) that targets higher-margin specialized segments, potentially reducing the company's reliance on commodity-grade Vitamin D3.
📅 குறுகிய காலம்Positive sentiment is expected as the AGM presentation highlights record core performance and a clear roadmap for high-value capacity expansion.
📈 நீண்ட காலம்Structural significance is high; if the ₹110 Cr capex successfully commercializes plant-source D3 and enzymes, it could lead to a margin-led re-rating over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Execution risk of the ₹110 Cr capex project
Product concentration in Vitamin D3
Regulatory compliance for new European market entry
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the ₹110 Cr Dahej expansion and the commercial ramp-up of plant-source Vitamin D3 in the European market following the CEP approval.
Fermenta Biotech Q1FY27: PAT Drops 56% YoY to ‹9.5 Cr; Human Nutrition Recovers 24% QoQ
Fermenta Biotech reported a weak Q1FY27 on a YoY basis, with PAT declining 56% to ‹9.5 Cr, largely due to a high base in Q1FY26 which included ‹4.3 Cr of non-recurring income. Revenue fell 13% YoY to ‹126.2 Cr, though the core Human Nutrition segment showed resilience with a 24% sequential (QoQ) revenue growth. Animal Nutrition remains a major headwind, with volumes down 52% QoQ and realizations dropping 40% YoY. The company is pivoting towards India, which now accounts for 47% of revenue compared to 35% a year ago.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company experienced a sharp profitability contraction YoY due to a high base and weak animal nutrition pricing, but saw a sequential volume recovery in its largest segment (Human Nutrition).
ஏன் இது முக்கியம்The results highlight the volatility of the Vitamin D3 market; the company's shift toward value-added products like Calcifediol and plant-based D3 is critical to reducing this cyclicality.
📅 குறுகிய காலம்The stock may face pressure due to the significant YoY decline in PAT and EBITDA margins, despite the sequential improvement in human nutrition.
📈 நீண்ட காலம்The structural shift toward the ‹110 Cr Dahej expansion and high-margin products like Calcifediol could re-rate the business if execution leads to margin expansion beyond the current 19% OPM.
⚠ அபாய எச்சரிக்கைகள்
Severe pricing pressure in Animal Nutrition
Rising employee costs ahead of revenue generation
High base effect volatility
👀 கவனிக்க வேண்டியவை
Monitor the commercialization timeline of Calcifediol and the market uptake of VITADEE Green following its July 2026 FSSAI approval. Investors should watch if the sequential recovery in Human Nutrition can offset the continued pricing pressure in the Animal Nutrition segment.
Fermenta Biotech has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The statutory auditors, M/s. SRBC & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting discrepancies. These results follow a fiscal year (FY26) where the company reported a revenue of ₹525 Cr and a PAT of ₹71 Cr. Investors should monitor if the company can improve its operating margins, which stood at 19% in FY26 compared to 25% in FY25.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formally released its financial performance data for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்As the first quarter of the new fiscal year, these results set the tone for FY27, especially after a year of margin compression (OPM fell from 25% to 19% in FY26).
📅 குறுகிய காலம்The stock price may react based on how the Q1 FY27 numbers compare to the ₹22 Cr PAT reported in the same quarter last year.
📈 நீண்ட காலம்The long-term focus remains on the company's ability to scale its pharmaceutical business while recovering operating margins toward historical highs of 25%.
⚠ அபாய எச்சரிக்கைகள்
Margin volatility (OPM dropped from 25% in FY25 to 19% in FY26)
High recent price run-up (95.6% in 3 months) may lead to profit booking if results are not exceptional
👀 கவனிக்க வேண்டியவை
Investors should compare the Q1 FY27 revenue and operating margins against the Q1 FY26 revenue of ₹136 Cr and PAT of ₹22 Cr to determine if the growth trajectory is sustaining.
Fermenta Biotech to list 2.94 crore equity shares on NSE effective August 04, 2026
Fermenta Biotech Limited has received approval to list its 2,94,30,987 equity shares on the National Stock Exchange (NSE) starting August 04, 2026. The company, which is currently listed on the BSE, will trade under the symbol 'FERMENTA'. This move is expected to enhance the stock's liquidity and visibility among institutional and retail investors. The company currently has a market capitalization of ₹1,355 crore and TTM revenue of ₹525 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is expanding its exchange presence by listing on the National Stock Exchange (NSE) in addition to its existing listing on the BSE.
ஏன் இது முக்கியம்Listing on the NSE is a significant milestone for a mid-cap company (₹1,355 Cr market cap) as it generally leads to higher trading liquidity, better visibility, and potential inclusion in broader market indices.
Total shares to be listed: 2,94,30,987ஒரு பங்கின் முக மதிப்பு: ₹5Listing date: ஆகஸ்ட் 04, 2026Market Capitalization: ₹1355 கோடிTTM வருவாய்: ₹525 கோடி
📅 குறுகிய காலம்Expect a potential increase in trading volumes and minor volatility as the stock begins trading on the NSE platform on August 4.
📈 நீண்ட காலம்Structural positive for the stock's liquidity profile; facilitates easier entry/exit for larger institutional investors over the coming quarters.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition of trading volumes from BSE to NSE starting August 4. While business fundamentals remain unchanged, the dual listing typically improves price discovery and accessibility for institutional funds.
Fermenta Biotech Proposes ₹3.75 Dividend and ₹100 Cr Related Party Transaction Limit
Fermenta Biotech has issued a notice for its 74th AGM scheduled for August 11, 2026. The company has proposed a dividend of ₹3.75 per share (75% of face value), representing a yield of approximately 0.87% at current prices. A significant agenda item is the approval of material related party transactions with its US step-down subsidiary, Fermenta USA LLC, for up to ₹100 crore. This transaction limit is substantial, representing roughly 19% of the company's TTM revenue of ₹525 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is seeking shareholder approval for its annual dividend payout and establishing a significant financial headroom for transactions with its US-based step-down subsidiary.
ஏன் இது முக்கியம்The ₹100 crore RPT limit indicates that the US subsidiary is a major component of the company's operational strategy. The dividend payout confirms the company's ability to return capital despite a moderate debt-to-equity ratio of 0.28.
Proposed Dividend: ₹3.75 per shareRPT Limit (Fermenta USA LLC): ₹100 கோடிRPT Limit vs TTM Revenue: 19.04%Director Commission Limit: 1% of net profitCost Auditor Remuneration: ₹2,75,000
📅 குறுகிய காலம்The stock may see minor interest due to the dividend announcement, though the yield is relatively modest at under 1%.
📈 நீண்ட காலம்The focus remains on the execution and revenue contribution from the US subsidiary, as evidenced by the large related party transaction mandate.
⚠ அபாய எச்சரிக்கைகள்
Significant related party transaction limit (₹100 Cr) with a step-down subsidiary.
Re-appointment of a director above the age of 75 requires a special resolution.
👀 கவனிக்க வேண்டியவை
Investors should monitor the AGM voting results, particularly the approval of the ₹100 crore transaction limit with the US subsidiary, to understand the scale of international operations and governance oversight.
Fermenta Biotech reported a record consolidated revenue of ₹548 Cr for FY26, a 14% YoY increase driven by strong Vitamin D3 demand. The company is pivoting towards patented innovation with a new process patent for plant-source Vitamin D3 and a ₹110 Cr capex plan at Dahej, representing ~21% of TTM revenue. While reported PAT dipped slightly to ₹70 Cr from ₹76 Cr due to lower real-estate income, core EBITDA grew 44% to ₹120 Cr. The balance sheet strengthened with net debt halving and cash flow from operations more than doubling to ₹93 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுTransition from a process-led manufacturer to a patented innovator in the Vitamin D3 space with a significant capacity expansion underway.
ஏன் இது முக்கியம்The ₹110 Cr capex targets high-growth segments like vegan Vitamin D3 and enzymes for the PLI-backed penicillin industry, diversifying revenue beyond traditional APIs and improving margin profiles.
FY26 Consolidated Revenue: ₹548 கோடிDahej Capex Program: ₹110 கோடிCapex vs TTM Revenue: ~21%Core EBITDA Growth: 44%Cash Flow from Operations: ₹93 கோடிFY26 Net Profit: ₹70 கோடி
📅 குறுகிய காலம்Positive sentiment is expected as the annual report confirms strong core operating momentum and a clear roadmap for high-value product launches.
📈 நீண்ட காலம்The structural shift towards patented plant-based Vitamin D3 and enzymes for the domestic penicillin industry could significantly re-rate the business over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Execution risk of the ₹110 Cr capex program
Volatility in global Vitamin D3 prices
Regulatory compliance for new clinical therapeutic lines
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the ₹110 Cr Dahej expansion and the commercial ramp-up of the newly patented plant-based Vitamin D3 products.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
